Academic Journal
Antiplatelets and antithrombotics in neurointerventional procedures: Guideline update.
| العنوان: | Antiplatelets and antithrombotics in neurointerventional procedures: Guideline update. |
|---|---|
| المؤلفون: | Schirmer, Clemens M, Bulsara, Ketan R, Al-Mufti, Fawaz, Haranhalli, Neil, Thibault, Lucie, Hetts, Steven W, Baxter, Blaise W, MD |
| المصدر: | Department of Radiology & Diagnostic Medical Imaging |
| بيانات النشر: | LVHN Scholarly Works |
| سنة النشر: | 2023 |
| المجموعة: | Lehigh Valley Health Network: LVHN Scholarly Works |
| مصطلحات موضوعية: | Department of Radiology and Diagnostic Medical Imaging, Diagnosis, Medicine and Health Sciences, Other Analytical, Diagnostic and Therapeutic Techniques and Equipment, Radiology |
| الوصف: | BACKGROUND: Antiplatelet and antithrombotic medication management before, during, and after neurointerventional procedures has significant practice variation. This document updates and builds upon the 2014 Society of NeuroInterventional Surgery (SNIS) Guideline 'Platelet function inhibitor and platelet function testing in neurointerventional procedures', providing updates based on the treatment of specific pathologies and for patients with specific comorbidities. METHODS: We performed a structured literature review of studies that have become available since the 2014 SNIS Guideline. We graded the quality of the evidence. Recommendations were arrived at through a consensus conference of the authors, then with additional input from the full SNIS Standards and Guidelines Committee and the SNIS Board of Directors. RESULTS: The management of antiplatelet and antithrombotic agents before, during, and after endovascular neurointerventional procedures continues to evolve. The following recommendations were agreed on. (1) It is reasonable to resume anticoagulation after a neurointerventional procedure or major bleeding episode as soon as the thrombotic risk exceeds the bleeding risk in an individual patient (Class I, Level C-EO). (2) Platelet testing can be useful to guide local practice, and specific approaches to using the numbers demonstrate marked local variability (Class IIa, Level B-NR). (3) For patients without comorbidities undergoing brain aneurysm treatment, there are no additional considerations for medication choice beyond the thrombotic risks of the catheterization procedure and aneurysm treatment devices (Class IIa, Level B-NR). (4) For patients undergoing neurointerventional brain aneurysm treatment who have had cardiac stents placed within the last 6-12 months, dual antiplatelet therapy (DAPT) is recommended (Class I, Level B-NR). (5) For patients being evaluated for neurointeventional brain aneurysm treatment who had venous thrombosis more than 3 months prior, discontinuation of oral anticoagulation ... |
| نوع الوثيقة: | text |
| اللغة: | unknown |
| Relation: | https://scholarlyworks.lvhn.org/radiology-diagnostic-medical-imaging/1045; https://pubmed.ncbi.nlm.nih.gov/37188504/ |
| الاتاحة: | https://scholarlyworks.lvhn.org/radiology-diagnostic-medical-imaging/1045 https://pubmed.ncbi.nlm.nih.gov/37188504/ |
| رقم الانضمام: | edsbas.7CF0A656 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |